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Chronic graft-versus-host disease (cGVHD)
remains the major cause of late morbidity
and mortality after allogeneic hematopoi-
etic stem cell transplantation (HSCT).
However, only a few studies specifically
focused on children, and little informa-
tion is available on the antileukemic ef-
fect of cGVHD and its impact on disease-
free survival (DFS) in children. We
retrospectively analyzed 696 children
given allogeneic HSCT for malignant
(n  450) or nonmalignant (n  246) dis-
eases. The donor was an HLA-identical
sibling in 461 cases and an alternative
donor in 235. Bone marrow was the stem
cell source in 647 cases, peripheral blood
in 17, and cord blood (CB) in 32. cGVHD
developed in 173 children (25%) at a me-
dian of 116 days after HSCT. Three-year
cGVHD probability was 27%. In multivari-
ate analysis, variables predicting cGVHD
were donor and recipient age, grade II to
IV acute GVHD, female donor for male
recipient, diagnosis of malignancy, and
use of total body irradiation; CB trans-
plants had a very low risk of cGVHD
(RR  0.07, P  .0001). cGVHD occur-
rence increased transplant-related mortal-
ity (P < .05). Nevertheless, in hemato-
logic malignancies, patients with cGVHD
had a reduced relapse probability com-
pared with children without cGVHD
(16%  3% versus 39%  3%, P  .0001)
and a better DFS (68%  4% versus
54%  3%, P  .01). The antileukemic ef-
fect of cGVHD was observed mainly in
patients with acute lymphoblastic leuke-
mia (ALL). This study provides novel data
on cGVHD in childhood. Use of CB stem
cells and preparative regimens without
radiotherapy may prevent its develop-
ment. In patients affected by ALL, cGVHD
was associated with a strong graft-versus-
leukemia effect, improving DFS. (Blood.
2002;100:1192-1200)
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Introduction
Chronic graft-versus-host disease (cGVHD) remains the most frequent
late complication after allogeneic hematopoietic stem cell transplanta-
tion (HSCT) and it represents the major cause of nonrelapse mortality
and morbidity in long-term survivors.1-3 In adults, the reported incidence
of cGVHD ranges between 30% and 50% of HLA-identical sibling
transplant recipients,1 with acute GVHD being recognized as the most
important factor predicting the development of the chronic form of the
disease.4-6 The increased use of matched unrelated volunteers as donors7
and of peripheral blood as a stem cell source8,9 has led to a further
increase of the incidence and severity of this complication.
Chronic GVHD is associated with a graft-versus-leukemia
effect (GVL), thus resulting, in the context of transplantation for
the treatment of hematologic malignancies, in a decreased inci-
dence of relapse.10-12 Nevertheless, the reduced relapse rate could
be offset by an increase in transplant-related mortality (TRM) and
counterbalanced by a severely impaired quality of life for patients
experiencing the extensive form of the disease.2,3
Previously published studies documented a lower risk of
cGVHD, as well as of acute GVHD, in younger patients.4-6
However, only a few studies specifically focused on children.13-15
For this reason, risk factors for cGVHD in childhood are still
poorly defined, and little information is available on the GVL effect
of this complication, as well as on its impact on disease-free
survival (DFS) and TRM of young patients.
We carried out a retrospective analysis on a large number of
children receiving allogeneic HSCT from either a matched or
mismatched family donor or an unrelated volunteer, to identify risk
factors predicting the development of cGVHD and to assess its
impact on clinical outcome.
Patients and methods
Patient characteristics
A total of 696 consecutive patients, undergoing allogeneic HSCT between
January 1, 1991, and June 30, 1999, in one of the transplantation centers of
the Italian Association for Pediatric Hematology and Oncology (AIEOP)
and reported to the AIEOP-BMT Registry were included in this analysis.
All new transplantations performed were registered yearly by each center,
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together with the updated follow-up of previously reported transplantations,
through disease- and transplant-specific data collection forms.
For the purpose of this study, only patients younger than 18 years of age
at the time of HSCT and surviving more than 90 days after the graft were
considered for data analysis. Exclusion criteria for the definition of the
study population comprised second or subsequent transplantations, the use
of a genotypically identical twin as donor, and a diagnosis of solid tumor.
In all donor-recipient pairs, histocompatibility was determined by
serology for HLA-A, B, and DR antigens, whereas high-resolution
molecular typing of HLA-class II DRB1 was available for all children
undergoing HSCT from an unrelated donor. A total of 450 children (65%)
had hematologic malignancies; the other 246 children (35%) had a
nonmalignant disorder. Children with acute leukemia receiving transplants
during first or second complete remission, those with myelodysplastic
syndrome (MDS) characterized by a low blast count (ie, refractory anemia
and refractory anemia with ringed sideroblasts), as well as patients with
chronic myeloid leukemia (CML) in first chronic phase were considered in
early phase, whereas all other patients with leukemia or MDS were
considered in advanced phase. Of the 696 patients analyzed, 418 were boys
and 278 girls. Median age at transplantation was 7 years (range, 0.3-17
years), whereas median donor age was 12 years (range, 0-55 years). The
donor was an HLA-identical sibling in 461 cases (66%), a partially matched
family donor in 68 cases (10%), and an unrelated volunteer in the remaining
167 patients (24%). The source of stem cells was bone marrow in 647 cases
(93%), peripheral blood in 17 (2%), and cord blood (CB) in 32 (5%).
GVHD prophylaxis consisted of cyclosporin A (Cs-A) alone in 343 cases
(49%) and Cs-A in combination either with methotrexate (MTX) in 127
cases (18%) or with steroids (prednisone [PDN]) in 62 cases (9%). The
combination of Cs-A  MTX  in vivo serotherapy (antilymphocyte
globulin [ALG] or the monoclonal antibody [mAb] Campath-1G) was
adopted for 102 transplants (15%). Nineteen patients (3%) received a
T-cell–depleted HSCT.
Details on the 696 patients evaluated, as well as on the transplantation
procedure, are reported in Table 1.
Diagnosis of acute and chronic GVHD and of chronic
GVHD resolution
The diagnosis of acute and cGVHD was made by the site investigators at
each institution on the basis of clinical symptoms, laboratory tests, and,
whenever possible, on histopathologic findings of skin, oral mucosa, and
gastrointestinal tract.16-18 Acute and cGVHD were classified according to
previously described criteria.19,20 Limited cGVHD was defined as either or
both localized skin involvement and hepatic dysfunction due to chronic
GVHD; extensive cGVHD was defined as generalized skin involvement, or
localized skin involvement or hepatic dysfunction due to cGVHD plus liver
histology showing chronic aggressive hepatitis, bridging necrosis or
cirrhosis, or involvement of the eye or minor salivary glands or oral
mucosa, or involvement or any other target organ.20,21
Resolution of cGVHD was defined as the disappearance of all active
lesions attributable to cGVHD (whenever possible confirmed by histopatho-
logic findings) or normalization of liver function tests, associated with the
discontinuation of any form of immunosuppressive treatment.
Treatment of chronic GVHD
The choice among the different options for treatment of cGVHD was based
on the policy in use in each single transplantation center and varied over
time. Thirty-three children received a single drug treatment (Cs-A alone in
20 cases, PDN alone in 11, ursodeoxycholic acid in 1, and mAbs in 1),
whereas the standard combination of Cs-A and PDN was used in 62
children, with the addition of azathioprine in 14. Thalidomide was used,
always in combination with Cs-A or steroids, in 14 patients. Fifteen
children received 3 or more immunosuppressive drugs. Extracorporeal
photochemotherapy was used, as single treatment modality or in combina-
tion with other systemic immunosuppressive drugs, in 26 children.22,23
Finally, 9 children, all with limited cGVHD, did not need any specific
immunosuppressive therapy.
Statistical analysis
The occurrence of cGVHD, as well as DFS, TRM, and relapse
probability according to cGVHD occurrence and extension, were
calculated by the Kaplan-Meier method; comparisons between
probabilities in different patient groups were performed using the
log-rank test.24 As suggested by Pepe et al,25 cGVHD was
presented, besides the Kaplan-Meier curve, also as the prevalence
of cGVHD over time after transplantation (Figure 1B). The
prevalence function at time t was calculated using the following
function: (number of patients with cGVHD at time t)/(number of
patients alive and relapse-free at time t).25,26
In DFS analysis, both relapse and death in remission due to any
cause were considered events, whereas in relapse probability
analysis, only disease relapse was considered as failure. In TRM
analysis, all deaths not due to disease recurrence were considered
events. Results were expressed as probability (%) and 95% CI.
Table 1. Patient characteristics
Characteristics and treatments Number Percentages
Number of patients 696
Sex, M/F 418/278 60/40
Median age at transplantation, y (range) 7 (0.3-17)
Diagnosis
Malignant disease 450 65
ALL 268 38
AML 99 14
CML 28 5
MDS 36 5
Lymphoma 19 3
Nonmalignant disease 246 35
Thalassemia 88 12
Severe aplastic anemia 35 5
Fanconi anemia 23 3
Immunodeficiencies 48 7
Inborn errors 52 8
Donor
HLA-identical family donor 461 66
Partially matched family donor 68 10
HLA-identical unrelated donor 141 20
Partially matched unrelated donor 26 4
Female donor/male recipient pairs 196 28
Median donor age, y (range) 12 (0-55)
Stem cell source
Bone marrow 647 93
Peripheral blood 17 2
Cord blood 32 5
Conditioning regimen
Chemotherapy based 369 53
TBI based 327 47
GVHD prophylaxis
Cs-A 348 50
Cs-AMTX 129 19
Cs-A PDN 63 9
Cs-AMTX ALG or mAb 104 15
Cs-A ALG or mAb PDN 33 5
T-cell depletion 19 2
Acute GVHD
Grade 0-I 406 58
Grade II-IV 290 42
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A univariate analysis of DFS, relapse probability, and TRM
according to cGVHD occurrence and severity was performed for
the whole study population and, subsequently, stratified for malig-
nant and nonmalignant disorders. Furthermore, a separate analysis
on the impact of cGVHD on relapse probability and DFS was
performed also for the 4 types of hematologic malignancies
including the larger number of patients: acute lymphoblastic
leukemia (ALL; 268 patients), acute myelogenous leukemia (AML;
99 patients), CML (28 patients), and MDS (36 patients).
In the univariate analysis of risk factors for cGVHD develop-
ment, the following variables were evaluated: patient and donor
age, sex mismatch, parity of female donors, diagnosis, type of
donor, stem cell source, use of total body irradiation (TBI) as part
of the conditioning regimen, GVHD prophylaxis, infused cell dose,
and development of grade II to IV acute GVHD. For this purpose,
continuous variables were categorized as follows: each variable
was first divided into 4 categories at approximately the 25th, 50th,
and 75th percentiles. If the relative event rates (ratio of the
observed number of events to the expected number of events in a
category, assuming no variation across categories) in 2 or more
adjacent categories (and the mean times-to-event) were not substan-
tially different, these categories were grouped together. If no clear
pattern was observed for the primary outcome, the median was
taken as the cut point.27
For the multivariate analysis of cGVHD, DFS, and relapse
probability, the Cox proportional hazard regression model was
used, including in the models all the variables with P  .05 in
univariate analysis.28,29
The 2 test was used to compare differences in percentages.
All P values were 2-sided and P  .05 was considered statis-
tically significant. P  .1 was reported as not significant (NS),
whereas P between .05 and .1 was reported in detail.
The SAS package (SAS Institute, Cary, NC) was used for the
analysis of the data.
Results
Data were analyzed as of December 31, 2000. Median follow-up
was 57 months (range, 18-119 months) for surviving patients and 9
months (range, 3.4-85 months) for patients not surviving.
Incidence of chronic GVHD and chronic GVHD resolution
Of the 696 patients analyzed, 173 (25%) developed cGVHD at a
median of 116 days after transplantation (range, 80-600 days). The
limited form of the disease was observed in 109 patients (16%), and
extensive cGVHD was diagnosed in 64 cases (9%). As shown in
Figure 1A, 2 years after the transplantation, the overall cumulative
probability of cGVHD was 27% (95% CI, 23%-30%). The
cumulative probabilities of developing either limited or cGVHD
were 17% (95% CI, 14%-20%) and 11% (95% CI, 8%-14%),
respectively.
For patients with cGVHD, median Karnofsky score at time of
last follow-up was 90%, with 72 of the 173 patients (42%) having a
Karnofsky score of 100% and only 7 (4%) with a Karnofsky score
below 50%.
The skin was the most common target of cGVHD, being
involved in 144 cases (83%); the liver was involved in 49 patients
(28%) and the gastrointestinal tract in 42 (24%). Oral cGVHD was
described in 12 patients (7%); both eye involvement and joint
contractures were reported in 6 cases (3%). Finally, 19 children
(11%) had lung involvement from cGVHD.
Figure 1B shows the prevalence of cGVHD over time after HSCT.
Prevalence was greater during the first year after HSCT, when it reached
a value of 18%, and progressively decreased to about 5% at 7 years after
transplantation. The prevalence of limited cGVHD was greater than that
of extensive cGVHD during the first 20 months after HSCT, whereas
the prevalence of extensive cGVHD was higher than that of limited
cGVHD from 20 months afterward.
Chronic GVHD resolved in 121 patients (70%), whereas it was
still present at the time of last follow-up or at time of death in the
remaining 52 children (30%). The median duration of cGVHD, in
the 121 patients in whom this complication resolved, was 5 months
(range, 1-93 months).
Figure 2 shows the cumulative probability of continuing
cGVHD, which was equal to 16% (95% CI, 6%-25%) 8 years after
transplantation, and the probability of death with cGVHD over
time after development of the complication, which was 12% (95%
CI, 3%-18%).
The analysis concerning the impact of cGVHD therapy on the
probability of cGVHD resolution and on patient outcome did not
show any statistically significant difference among the different
treatment modalities (data not shown).
Risk factors for chronic GVHD
A number of demographic and transplant-related characteristics
were evaluated as potential risk factors for cGVHD. Tables 2 and 3
Figure 1. Cumulative probability of developing cGVHD and its prevalence.
(A) Overall cumulative probability to develop cGVHD after HSCT in our study
population and probability to develop the limited or the extensive form of the disease.
(B) Overall prevalence of cGVHD and prevalence of the limited and extensive form of
the disease. The prevalence function at time t was calculated using the following
function: (number of patients with cGVHD at time t )/(number of patients alive and
relapse-free at time t ).
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present the results of univariate and multivariate analysis of risk
factors for development of cGVHD.
Several variables were strongly associated with an increased
risk of cGVHD in univariate analysis. In particular, older patient
age was significantly associated with cGVHD, with children
younger than 5 years having a probability of less than 14% of
developing this complication, those aged 5 to 15 years a probability
of about 30%, and those older than 15 years a probability of 44%
(P  .0001). Also donor age was a significant risk factor for
cGVHD occurrence in univariate analysis, with a continuous
increase in the incidence of this complication from less than 10%
for donors younger than 5 years, to more than 40% for donors older
than 40 years of age (P  .0002). Female donor and male recipient
combination was another factor predicting cGVHD development
(34% versus 23%, P .01). Furthermore, patients affected by hemato-
logic malignancies had a greater incidence of cGVHD (35% versus
13%, P .01), as well as those treated with TBI (38% versus 17%,
P .0001) and those with previous grade II to IV acute GVHD (45%
versus 14%, P .0001). CB transplants had a significantly lower
probability of cGVHD (3%) compared with bone marrow or peripheral
blood transplants (28%, P .0073). As reported in Table 2, in our
cohort of patients, parity of female donors did not show any effect on the
risk of cGVHD development.
In multivariate analysis, the following 6 characteristics were
associated with an increased probability of developing cGVHD:
patient age 15 years or older (RR 1.82, P  .03), donor age 5
years or older (RR 3.36, P  .001), female donor and male
recipient (RR 1.52, P  .01), use of TBI as part of the condition-
ing regimen (RR 1.56, P  .02), diagnosis of hematologic
malignancy (RR 1.80, P  .01), and, with the highest relative
risk, previous grade II to IV acute GVHD (RR 2.14, P  .0001).
On the contrary, transplants of CB stem cells were characterized by
a very low incidence of cGVHD, with only 1 child of 32 presenting
this complication (RR 0.07, P  .001).
Causes of death and TRM
Overall, 191 (27%) of the 696 patients analyzed died; 146 (28%)
belonged to the group of 523 subjects without cGVHD, whereas 45
(26%) belonged to the 173 children with cGVHD.
Details on the causes of death for patients with and without
cGVHD are reported in Table 4. Disease progression was the main
Figure 2. Cumulative probability of continuing cGVHD and of death with cGVHD
over time after the onset of cGVHD. To calculate the probability of continuing
cGVHD, cGVHD resolutions were considered as events, whereas patients whose
cGVHD did not resolve were censored at time of last follow-up or of death. To
calculate the probability of death with cGVHD, only deaths with active cGVHD were
considered events, whereas patients whose cGVHD resolved were censored at time
of last follow-up or death.
Table 2. Univariate analysis of risk factors for cGVHD development
Univariate analysis
No. of
cases Events
Probability,
% (95% CI) P
Patient age
Younger than 2 y 108 9 9 (3-14) .0001
2-5 y 122 27 14 (16-31)
5-10 y 239 67 30 (24-36)
10-15 y 170 46 29 (22-37)
15 y or older 57 24 44 (31-58)
Donor age
Younger than 2 y 49 2 4 (0-10) .0002
2-5 y 84 8 10 (3-16)
5-10 y 139 32 25 (17-32)
10-15 y 100 26 27 (18-36)
15-20 y 75 21 30 (19-40)
20-30 y 96 30 36 (25-46)
30-40 y 96 31 39 (29-49)
40 y or older 49 19 42 (27-57)
Unknown 8 4
Sex
Female donor and male
recipient 196 62 34 (27-41) .01
Other 497 109 23 (20-27)
Unknown 3 2
Parity*
Female donor, no pregnancy 34 18 58 (40-76) NS
Female donor, 1 or more
pregnancies 37 15 44 (27-61)
Diagnosis
Nonmalignant disease 246 31 13 (9-17) .001
Malignant disease 450 142 35 (30-39)
Donor
HLA-identical family 461 105 24 (20-28) .019
Partially matched family 68 15 27 (15-39)
HLA-identical unrelated 141 48 37 (29-46)
Partially matched unrelated 26 5 20 (4-35)
Stem cell source
Bone marrow 647 168 28 (24-31) .027
Peripheral blood 17 4 30 (4-55)
Cord blood 32 1 3 (0-9)
Stem cell source
Bone marrow peripheral
blood 664 172 28 (24-31) .0073
Cord blood 32 1 3 (0-9)
Conditioning regimen
Chemotherapy based 369 60 17 (13-21) .0001
TBI based 327 113 38 (33-44)
GVHD prophylaxis
Cs-A 348 82 25 (20-30) .0052
Cs-AMTX 129 32 27 (19-35)
Cs-A PDN 63 13 23 (12-34)
Cs-AMTX ALG or mAb 104 39 42 (31-42)
Cs-A ALG or mAb PDN 33 4 15 (1-29)
T-cell depletion 19 3 16 (0-32)
GVHD prophylaxis
Cs-AMTX ALG or mAb 104 39 42 (31-52) .0001
Other prophylaxis 592 134 24 (21-28)
Cell dose infused
Less than 2 108/kg 117 37 35 (26-44) .09
2 108/kg or more 556 132 25 (21-29)
Unknown 23 4
Acute GVHD grade
Grade 0-I 406 54 14 (11-18) .0001
Grade II-IV 290 119 45 (39-51)
*The impact of parity on cGVHD occurrence was evaluated in the 117 donor-
recipient pairs with a female donor older than 20 years; data on parity were available
for 71 of these 117 donors (61%).
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cause of death in 102 patients, whereas 89 children died of
transplant-related causes. In patients with cGVHD, we observed a
significantly higher percentage of transplant-related deaths (69%) as
compared to subjects without cGVHD (40%), and a lower percentage of
deaths due to disease progression (31% versus 60%, P .0006). In the
group of children who had cGVHD, this complication was indicated as
the primary cause of death in 11 of the 31 patients who died due to
transplant-related causes (35%), so that 6% of the 173 patients with
cGVHD died because of this complication.
In the 11 cases where cGVHD was reported as the main cause of
death, the ultimate cause of death was bronchiolitis obliterans in 4 cases,
cytomegalovirus interstitial pneumonia in 1 case, bacterial pneumonia in
1 case, other bacterial infections in 3 cases, hemorrhagic complications
in 1 case, and multiorgan failure in 1 case.
For patients treated for nonmalignant disorders, the cumulative
probability of TRM was 13% (95% CI, 7%-19%) for children
without cGVHD, 5% (95% CI, 0%-15%) for those with the limited
form of the disease, and 64% (95% CI, 11%-100%) for those with
extensive cGVHD (P  .016). For subjects treated for malignant
diseases, the cumulative probability of TRM was 9% (95% CI,
5%-13%) for children without cGVHD, 15% (95% CI, 5%-25%)
for those with limited disease, and 24% (95% CI, 12%-36%) for
those with extensive cGVHD (P  .036).
Relapse probability
Of the 450 children who underwent HSCT for treatment of
hematologic malignancy, 127 (28%) experienced disease relapse.
Analyzing the risk of relapse according to cGVHD occurrence, we
observed that the 6-year cumulative relapse probability was
significantly lower (P  .0001) in children with cGVHD, being
16% (95% CI, 10%-22%) compared with a value of 39% (95% CI,
33%-45%) in patients without cGVHD (Figure 3).
Tables 5 and 6 show the results of univariate and multivariate
analysis of the probability of relapse in the 450 children affected by
hematologic malignancies. cGVHD confirmed its protective effect
against relapse also in multivariate analysis (RR 0.32, P .0001, for
patients with cGVHD versus those without cGVHD).
Stratifying the analysis by type of malignancy, we observed that
the GVL effect associated with cGVHD was stronger in the 268
patients with ALL. In fact, the relapse probability for children with
ALL and cGVHD was 14% (95% CI, 6%-21%) compared with the
47% (95% CI, 39%-54%) observed in children with ALL but
without cGVHD (P  .0001). On the contrary, for the 99 patients
with AML, the relapse probability was identical (29%) in both
groups of patients. Among the 20 children with MDS, development
of cGVHD was associated with a lower relapse probability, even
Figure 3. Six-year relapse probability after HSCT for children affected by
hematologic malignancies, according to cGVHD development. Patients experi-
encing cGVHD had a significantly lower risk of relapse (P  .0001).
Table 3. Multivariate analysis of risk factors for cGVHD development
Multivariate analysis
RR (95% CI) P
Patient age
Younger than 5 y 1.00
5-15 y 1.39 (0.93-2.08) .1
15 y or older 1.82 (1.06-3.12) .03
Donor age
Younger than 5 y 1.00
5-20 y 3.26 (1.57-6.77) .001
20 y or older 5.73 (2.56-12.8) .0001
Sex
Female donor and male recipient vs others 1.52 (1.11-2.07) .01
Diagnosis
Malignant vs nonmalignant 1.80 (1.13-2.88) .01
Donor
HLA-identical family vs other donors .69 (0.41-1.17) NS
Stem cell source
CB vs bone marrow peripheral blood .07 (0.03-0.16) .0001
Conditioning regimen
TBI vs chemotherapy 1.56 (1.08-2.26) .02
GVHD prophylaxis
Cs-AMTX ALG or mAb vs other
prophylaxis 1.55 (0.92-2.51) .08
Acute GVHD grade
Grade II-IV vs grade 0-I 2.14 (1.78-2.59) .0001
Table 4. Causes of death for patients with and without cGVHD
No chronic
GVHD
(523 patients)
Chronic
GVHD
(173 patients)
Total
(696 patients)
Disease progression (%) 88 (60) 14 (31) 102 (53)
Transplant-related causes (%) 58 (40) 31 (69) 89 (47)
Bacterial pneumonia 5 3
HCMV interstitial pneumonia 2 0
Bacterial infection 10 5
Fungal infection 4 4
Viral infection 0 1
EBV-PTLD 2 0
Encephalitis 2 0
ARDS 5 1
Idiopathic interstitial pneumonia 5 1
Autoimmune hemolytic anemia 2 0
Thrombotic thrombocytopenic
purpura 2 0
Liver failure 2 0
Renal failure 0 1
Cardiac insufficiency 1 0
Multiorgan failure 6 2
Hemorrhage 10 2
cGVHD 0 11
Total 146 45 191
2  11.76, P  .0006 for the comparison of causes of death (disease
progression versus transplant-related cause) in subjects with and without cGVHD.
For the 11 patients with cGVHD reported as the main cause of death, the ultimate
cause of death was bronchiolitis obliterans in 4 cases, HCMV interstitial pneumonia in
1 case, bacterial pneumonia in 1 case, other bacterial infections in 3 cases,
hemorrhagic complications in 1 case, and multiorgan failure in 1 case. HCMV
indicates human cytomegalovirus; EBV-PTLD, Epstein-Barr virus–related posttrans-
plantation lymphoproliferative disease; ARDS, acute respiratory distress syndrome.
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though the advantage was not statistically significant (0% versus
36%, P  .053). Because only 3 of the 28 children with CML
experienced a relapse, it was impossible to analyze the role of
cGVHD on leukemia recurrence in this group of patients.
Survival and DFS
Overall, 482 of the 696 patients analyzed (69%) are alive
and disease free, with a cumulative probability of DFS of 67%
(95% CI, 63%-71%).
Figure 4 shows the 6-year cumulative probability of DFS for
patients with either nonmalignant disorders (Figure 4A) or hemato-
logic malignancies (Figure 4B), respectively. For children with
nonmalignant diseases, no statistically significant difference was
observed for DFS between patients without or with cGVHD (85%
versus 77%, P  NS), this finding being due to the fact that most of
patients with cGVHD had the limited form of the disease. On the
Figure 4. Probability of DFS. Six-year probability of DFS according to the
development of cGVHD is shown for patients affected by nonmalignant disorders (A)
and for those affected by hematologic malignancies (B). The difference was not
statistically significant for nonmalignant disorders, whereas in the group of patients
affected by malignant diseases, the advantage for subjects with cGVHD was
statistically significant (P  .0013).
Table 5. Univariate analysis of relapse probability in the 450 patients
with malignant disease
Univariate analysis
Number of
cases Events
Probability,
% (95% CI) P
Patient age
Younger than 5 y 110 30 28 (20-37) NS
5-10 y 174 51 34 (26-41)
10-15 y 125 32 29 (20-38)
15 y or older 41 14 41 (22-60)
Donor age
Younger than 5 y 81 23 31 (20-42) NS
5-10 y 95 24 27 (17-36)
10-15 y 64 18 33 (19-46)
15-20 y 55 14 28 (15-40)
20-30 y 69 22 34 (23-46)
30-40 y 56 17 37 (21-52)
40 y or older 30 9 44 (15-72)
Sex
Female donor and male
recipient 103 20 21 (13-29) .0706
Other 320 90 32 (26-38)
Diagnosis
ALL 268 87 35 (29-41) NS
AML 99 24 31 (19-42)
MDS 36 8 25 (10-40)
CML 28 3 18 (0-39)
Lymphoma 19 5 28 (7-49)
Disease phase
Early 285 66 26 (21-32) .0003
Advanced 165 61 42 (34-51)
Donor
HLA-identical family 306 85 30 (25-36) NS
Other donor 144 42 36 (26-46)
Stem cell source
Bone marrow peripheral
blood 434 121 31 (26-36) NS
Cord blood 16 6 52 (19-85)
GVHD prophylaxis
Cs-AMTX ALG or mAb 81 25 34 (23-45) NS
Other prophylaxis 369 102 31 (26-36)
Conditioning regimen
Chemotherapy based 148 41 33 (24-43) NS
TBI based 302 86 31 (26-37)
Acute GVHD
0-I 223 77 38 (31-45) .0005
II-IV 227 49 25 (18-31)
Chronic GVHD
Absent 308 107 39 (33-45) .0001
Present 142 20 16 (9-22)
Chronic GVHD
Absent 308 107 39 (33-45) .0001
Limited 89 16 20 (11-28)
Extensive 53 4 10 (0-19)
Table 6. Multivariate analysis of relapse probability in the 450 patients
with malignant disease
Multivariate analysis
RR (95% CI) P
Sex
Female donor and male recipient vs others 0.82 (0.56-1.21) NS
Disease phase
Advanced vs early 2.11 (1.48-3.00) .0001
Acute GVHD
II-IV vs 0-I 0.91 (0.65-1.27) NS
cGVHD
Present vs absent 0.32 (0.20-0.52) .0001
Variables with P  .1 in univariate analysis were included in the multi-
variate analysis.
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contrary, considering children receiving transplants for malignant
diseases, patients who developed cGVHD had a significantly better
DFS, as compared to children without cGVHD (68% versus 54%,
P  .0013).
Tables 7 and 8 summarize the results of univariate and
multivariate analysis of DFS probability for the 450 children
affected by malignant diseases. As for relapse, the positive impact
of cGVHD on DFS was confirmed also in multivariate analysis,
where this variable was associated with a relative risk of DFS of
2.07 (P  .0001).
As already observed for relapse probability, also for DFS the
favorable influence of cGVHD was observed only for children with
ALL, where the cumulative probability of DFS was 74% (95% CI,
64%-83%) for patients developing cGVHD and 47% (95% CI,
38%-53%) for children without cGVHD (P  .0001), whereas the
effect on other hematologic malignancies was nonsignificant. In
fact, in the 99 patients with AML, the DFS probability was 59%
(95% CI, 36%-82%) for children with cGVHD and 68% for those
without cGVHD (P  NS), and in the 28 children with CML it was
64% (95% CI, 35%-92%) and 71% (95% CI, 44%-97%) for
subjects with and without cGVHD, respectively (P  NS). Finally,
also considering the 20 children with MDS, the outcome of patients
with and without cGVHD was similar, DFS being 67% (95% CI,
36%-97%) and 64% (95% CI, 35%-92%), respectively (P  NS).
Discussion
Chronic GVHD remains a substantial problem of allogeneic HSCT.
Several studies, published in recent years, introduced the notion
that recipient age is a major risk factor for the development of
cGVHD and that children have a lower probability of presenting
this complication.4-6 However, this information, as well as our
clinical knowledge of cGVHD and of its risk factors, are based
primarily on results of analyses performed in adults.
In our study, conducted on the largest pediatric population
reported so far, we observed a cumulative probability of cGVHD of
27%, which is similar to probabilities ranging from 22% to 29%
reported by 3 other analyses conducted on smaller cohorts of
pediatric patients in recent years.13-15 This probability is nearly half
of the estimated probability of 40% to 50% described in adults.4-6
In our group of patients younger than 18 years, older patient and
donor age were predictive of a higher risk of cGVHD both in
univariate and in multivariate analysis. On the other hand, the type
of donor and of GVHD prophylaxis was not predictive of the
development of this complication. In multivariate analysis, other
factors, such as the female donor–male recipient combination, a
diagnosis of malignant disease, the use of TBI, and, as expected,
previous grade II to IV acute GVHD, were characterized by a
significantly higher risk of cGVHD. Furthermore, in agreement
with the observation of Rocha et al,30 use of CB progenitor cells
was confirmed to be characterized by a very low probability of
cGVHD. In contrast, we could not confirm the observation of an
increased risk of cGVHD in subjects receiving peripheral blood
stem cells.8,9 This was possibly due to the limited number of
patients receiving peripheral blood stem cells.
Table 7. Univariate analysis of DFS probability in the 450 patients
with malignant disease
Univariate analysis
No. of
cases Events
Probability,
% (95% CI) P
Patient age
Younger than 5 y 110 35 66 (56-76) NS
5-10 y 174 72 57 (49-64)
10-15 y 125 52 57 (48-66)
15 y or older 41 17 54 (35-72)
Donor age
Younger than 5 y 81 31 61 (50-72) .09
5-0 y 95 31 65 (55-76)
10-15 y 64 22 63 (49-76)
15-20 y 55 18 65 (52-78)
20-30 y 69 32 52 (40-64)
30-40 y 56 24 48 (34-62)
40 y or older 30 14 45 (21-70)
Sex
Female donor and male
recipient 103 53 59 (50-67) NS
Other 320 123 59 (53-65)
Diagnosis
ALL 268 116 56 (50-62) NS
AML 99 30 64 (53-76)
MDS 36 15 54 (35-73)
CML 28 8 66 (45-87)
Lymphoma 19 7 63 (41-85)
Disease phase
Early 285 93 65 (59-71) .0001
Advanced 165 83 48 (39-56)
Donor
HLA-identical family 306 103 65 (59-70) .0003
Other donors 144 73 45 (34-55)
Stem cell source
Bone marrow peripheral
blood 434 167 59 (54-64) .1032
Cord blood 16 9 38 (9-66)
GVHD prophylaxis
Cs-AMTX ALG or mAb 81 39 51 (39-62) .0533
Other prophylaxis 369 167 61 (55-66)
Conditioning regimen
Chemotherapy based 148 52 59 (50-69) NS
TBI based 302 124 58 (52-64)
Acute GVHD
0-I 223 89 58 (51-65) NS
II-IV 227 87 60 (53-67)
cGVHD
Absent 308 134 55 (49-60) .0013
Present 142 42 68 (60-76)
cGVHD
Absent 308 134 55 (49-60) .0055
Limited 89 26 68 (58-79)
Extensive 53 16 68 (54-81)
Table 8. Multivariate analysis of DFS probability in the 450 patients
with malignant disease
Multivariate analysis
RR (95% CI) P
Donor age
Younger than 20 y vs 20 y or older 1.23 (0.79-1.90) NS
Disease phase
Advanced vs early 0.57 (0.42-0.78) .0004
Donor
HLA-identical family vs other donors 1.52 (0.95-2.43) .08
GVHD prophylaxis
Cs-AMTX ALG or mAb vs other prophylaxis .97 (0.58-1.64) NS
cGVHD
Present vs absent 2.04 (1.43-2.91) .0001
Variables with P  .1 in univariate analysis were included in the multi-
variate analysis.
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Our study confirms previously published reports documenting
that male patients given a transplant from a female donor experi-
ence more GVHD,6 an observation that has been biologically
explained hypothesizing that male antigens (ie, H-Y) not shared by
females are recognized and attacked by the donor’s immune
system.31,32 However, our data are particularly intriguing because
most female donors were young and, thus, not sensitized toward
male antigens by previous pregnancies. Furthermore, even if
evaluated on a limited number of subjects, parity of female donors
was not a risk factor for cGVHD development; this suggests that
even a primary immune response toward these molecules may
produce cGVHD.
Children with nonmalignant disorders had a reduced risk of develop-
ing cGVHD. Several factors may be considered to explain this
observation. Because children with these diseases do not benefit at all
from GVHD, it is reasonable to hypothesize that the most effective
pharmacologic strategies for both GVHD prevention and therapy of
acute GVHD were used in these patients. Moreover, it has been already
reported that these patients can have a mixed chimerism,33-35 and this
condition is associated with reduced susceptibility to GVHD, probably
through mechanisms of central tolerance with negative selection of both
host-reactive and donor-reactive T cells.36 Finally, some of the children
with nonmalignant disorders (ie, those with aplastic anemia or with
congenital immunodeficiencies) were given less intensive preparative
regimens and it has been hypothesized that the cytokine storm, which is
dependent on the intensity of the conditioning regimen, triggers
development of GVHD.37 In this regard, the finding of an increased risk
of cGVHD in children given TBI as part of the preparative regimen
is also of particular interest. Moreover, because it has been
suggested as a relevant role of recipient’s thymus in promoting
tolerance of donor cells, we speculate that the higher risk of
cGVHD in children given TBI can be partly explained by a
radiation-induced damage to thymic epithelial cells.38-40
We also found an increased risk of cGVHD in patients receiving
a transplant from an older donor. The detrimental effect of
increased donor age on cGVHD has been recently reported in a
cohort of patients given HSCT from unrelated volunteers.41 The
biologic mechanisms accounting for this effect of donor age remain
unclear and deserve further investigation.
Considerable experimental and clinical data suggest a role of
the immune system in controlling cancer and, particularly, leuke-
mia, through the GVL effect.12,42-45 In our study, we document a
strong protective effect of cGVHD against relapse in children withALL,
whereas the advantage was lower and not statistically significant for
patients with MDS and absent for those with AML. Moreover, in
children with ALL, the increased TRM associated with cGVHD was
largely offset by the impressive reduction in relapse probability, thus
resulting in a significantly better survival and DFS.
Despite a beneficial GVL effect against relapse, cGVHD
remains a major determinant of poor long-term outcome and of
impaired quality of life after allogeneic HSCT.2 For this reason,
several efforts have been made to identify factors having an
unfavorable prognostic significance, to select subjects with higher
risk of either death or invalidating sequelae (as severe joint
contractures requiring physical therapy, impairment of lung func-
tion, keratoconjunctivitis sicca with corneal lesions, malnutrition
due to gastrointestinal involvement), who need to be treated
promptly and more intensively.46-49 Over the last few years, new
drugs and different treatment modalities have been developed for
patients with cGVHD,50 even though the optimal treatment is still
controversial and no single therapy has been demonstrated to be
superior and most effective.51
In our study population, subjects developing cGVHD had a
significantly higher TRM, as compared to those without the
disease, even though only 6% of children with cGVHD died
directly or indirectly because of this complication. The negative
effect of cGVHD was particularly evident in patients with the
extensive form of the disease and for those affected by nonmalig-
nant disorders. These observations emphasize the need for a more
effective prophylaxis for patients undergoing transplantation with
the aim of curing nonmalignant disorders and a more effective
treatment for those with extensive GVHD or with poor prognostic
clinical features.
Our data document that children have a lower incidence of
cGVHD compared with adults. Use of CB stem cells and of
conditioning regimens without TBI, as well as better strategies for
preventing acute GVHD occurrence, could further decrease the risk
of this complication. We provide evidence for a strong antileuke-
mia effect of cGVHD for ALL, but not for other hematologic
malignancies. Despite an increased TRM, the probability of DFS in
ALL was not impaired by the occurrence of this complication.
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